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Background: Inflammatory Bowel Disease (IBD) patients report poorer quality of life (QoL) and more anxiety and
depressive symptoms than controls from the general population. Cognitive behavioral therapy (CBT) is effective for
anxiety and depression, but questionable in case of co-morbidity with IBD. Therefore, an adapted new CBT
specifically designed for IBD patients was developed. The objective of this study is to evaluate the effectiveness of
adapted CBT on QoL.
Methods/design: IBD patients with a poor level of mental QoL (score less than or equal to 23 on the mental
health scale of SF-36) will be randomly assigned to the experimental (n = 40) or waiting-list control condition
(n = 40). The experimental condition will then immediately start CBT. The waiting-list control condition will wait
3,5 months before CBT begins with pre- and post assessments. Both conditions will complete a baseline and
follow-up assessment following CBT and a mid-treatment assessment. The primary outcome is IBD-specific QoL
(IBDQ). Secondary outcomes are generic QoL (SF-36) and anxiety and depression complaints (HADS, CES-D).
Additionally, we will examine the working mechanism of the psychological intervention by investigating the impact
of the intervention on illness-related cognitions, attitudes, coping styles and their associations with outcome. Data
will be analysed on an intention to treat (ITT) as well as treatment completer basis (greater than or equal to five
sessions followed).
Discussion: If found effective, this IBD-specific CBT is a first step to enhance poor QoL in IBD patients and possibly,
other gastroenterological diseases. By enhancing IBD patients’ QoL, we may also improve their mental and physical
health, and lower unnecessary health care consumption.
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According to the 2010 international Inflammatory Bowel
Disease (IBD: Crohn’s disease and ulcerative colitis) task
force meeting, incidence and prevalence of IBD is stead-
ily increasing worldwide [1]. However, in high-incidence
regions such as North America, the United Kingdom
and Northern Europe the rates of IBD have stabilised
[1,2]. In 2000, the incidence and prevalence of CD in
North America were approximately 8 and 174 per
100,000, respectively and for UC approximately 8 and
214 per 100,000 respectively [3]. In Northern Europe
these figures are slightly lower [2]. Approximately 50,000
people in the Netherlands have medically confirmed
IBD. Each year this group increases with 2500 new
patients [4]. IBD cannot be cured and the exact cause is
unknown. The course of the disorder varies in severity
but is characterized by unpredictability and is accom-
panied by physical symptoms such as diarrhoea, bowel
spasms, faeces containing blood or mucus, qualms and
fever attacks. Additionally, the medical treatments that,
in some cases require life-long administration, often in-
duce side effects and complications, such as weight gain,
a moon face, eczema and acne. Peri-anal complications
such as abscesses and fistulas severely affect quality of
life by impairing sexual function and faecal continence
and are a cause of chronic pain. Other manifestations
such as spondylarthropathy may cause significant mor-
bidity. Furthermore, many patients require surgical treat-
ment in the course of their disease. Surgery frequently
results in a permanent ileostoma or colostoma [5,6].
Moreover, chronic immune suppression that results from
medical treatment increases the risk of hematological
malignancies. Finally, since IBD is associated with an
increased risk of colorectal cancer, patients undergo
frequent endoscopic surveillance [7].
Consequently, the quality of life of IBD patients is
impaired. Individuals with IBD have been found to
report poorer quality of life and more anxiety and
depressive symptoms than comparison-controls from
the general population [8,9]. Many IBD patients are con-
fronted with fatigue, pain, embarrassment and physical
disablement that have negative effects on social and
work life. Poor quality of life in turn, has a negative
impact on relapse and disease activity [10].
Recent studies and clinical experience suggest that
higher levels of anxiety and depressive symptoms in IBD
patients are not only related to disease activity and
severity. Individual characteristics also affect patients’
experienced distress, especially those associated with
illness-related cognitions and attitudes [11]. Specific
IBD-related cognitions (e.g. ‘I will never find a partner
because of my colostomy bag’; ‘I can’t have sex because I
am dirty’; ‘It makes no sense to invest in new work or
personal relations because of the unpredictability of myillness’) and (premorbid) attitudes like perfectionism
(‘Everything has to be perfect otherwise I am worthless’),
dependency (‘Without the help of others I will not sur-
vive’) and mistrust (‘In the end other people will always
let me down’) are highly influential in terms of ability to
cope with IBD.
Of the psychotherapeutic intervention techniques that
have been investigated, the most promising intervention
for amending such dysfunctional cognitions and attitudes
is cognitive behavioral therapy (CBT) [12]. This therapy
posits that individual’s biased information processing leads
to restrictive thoughts, feelings and behaviors that can
culminate in anxiety and depressive symptoms and eventu-
ally in psychiatric disorders. CBT offers a well-developed
intervention protocol that has been found to enhance qual-
ity of life and to decrease psychological distress. It has been
found to be effective in people with other chronic illnesses
such as chronic obstructive pulmonary disease, diabetes
[13], and cancer [14].
A recent meta-analysis of 21 studies was conducted
that evaluated the effect of psychological treatment on
quality of life, emotional status and disease activity
in IBD [15]. The psychological treatments included
psycho-education as intervention (10 studies), stress
management (3 studies), psychotherapy (6 studies) and
other non-specific techniques like a support group
(2 studies). Of all included studies only 6 studies evalu-
ated the effect of a multi modular approach including
IBD psycho-education (4 of them included CBT techni-
ques). Overall, no significant effects of psychological
interventions were found on improving health related
quality of life, emotional problems and disease activity.
All studies included suffered from various methodo-
logical shortcomings such as small sample sizes and
non-random sampling. Moreover, all but one study
included patients who did not have elevated levels of
distress, thereby diluting the treatment effect. Patients
in these studies seemed relatively healthy, so perhaps
there was no room for improvement. Inclusion of
patients with higher anxiety and depressive symptoms
may have resulted in more positive effects. Only one
study selected patients based on HADS anxiety levels
[16]. Given these methodological shortcomings and the
many multi-component interventions, it is still unclear
what the effects of a specific CBT are. We have, there-
fore, developed a CBT that is specifically designed for
patients with IBD who have a poor quality of life,
thereby targeting a patient group that is most burdened
by the illness.
We will examine the effectiveness of CBT in this study
by using a randomized waiting-list control design, in-
cluding a sufficiently large number of patients who have
elevated levels of mental distress. This paper contains a
detailed description of the design of this randomized
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specifically designed for IBD patients.
Trial objectives and purpose
The primary objective is to investigate the effectiveness
of individual CBT in a sample of IBD patients. Our
primary outcome is the effect on IBD-specific quality of
life (IBDQ). The secondary outcome is the effect of CBT
on generic quality of life (SF-36), anxiety and depression
complaints (HADS, CES-D) and illness activity (P-HBI
and P-SCCAI). The secondary objective is to investigate
the extent to which changes in quality of life and anxiety
and depression are mediated by improvements in cogni-
tions, attitudes and coping styles.
Our primary hypothesis states that cognitive behav-
ioral therapy will improve quality of life, and reduce anx-
iety and depression. Our secondary hypothesis states
that improvements in quality of life are mediated by
changes in illness cognitions, attitudes and coping styles
(avoidant and problem solving coping).
Methods and design
The present study is a multi-center randomized clinical
trial (see Figure 1). All patients with ulcerative colitis or
Crohn’s disease attending the out-patient departments of
the Academic Medical Center (AMC), VU University
Amsterdam (VUmc), Flevo-hospital and Slotervaart-
hospital will complete a 36-item questionnaire assessing
generic health-related quality of life or health status
(SF-36) prior to the consultation. This questionnaire will
be administered as part of standard care. The nurse
practitioner will be present and can be contacted for fur-
ther information and help. Patients who score at or
below the cut-off score of 23 on the mental health sub-
scale will be eligible for the study [17]. If these patients
are also 18 years or older, have a diagnosis of Crohn’s
disease or ulcerative colitis and have sufficient command
of Dutch, they will be given the informed consent letter
by their treating gastroenterologist. After one week they
will be contacted by telephone by the researcher to pro-
vide further information and/or clarification if needed.
Also the researcher will check whether informed consent
is received. If patients agree to participate, an appoint-
ment will be made to sign the informed consent letter in
the presence of the researcher. Participants will be glo-
bally screened based on main study inclusion criteria
(i.e. physically and mentally able to attend eight weekly
sessions and willing to give written informed consent)
and exclusion criteria (i.e. current treatment with psy-
chotherapy). During this meeting an appointment will
be scheduled for the administration of the Structural
Clinical Interview for DSM-IV Disorders-I (SCID-I) that
assesses Axis-I psychiatric diagnoses to determine fur-
ther psychiatric exclusion criteria and to examinepsychiatric disorders within this population (for instance
anxiety and depression disorders) [18]. Patients will be
further excluded from the study if they have current
substance dependence or abuse, or psychosis.
The SCID-I will be administered by telephone, by
psychologists who received a specific training for this.
All patients will then be asked to complete a set of
questionnaires that assess the baseline primary and
secondary outcomes via the web (see Table 1). If patients
prefer paper and pencil completion, these questionnaires
will be sent. After completion of the first baseline assess-
ment, patients will be randomly assigned to the experi-
mental or waiting-list control condition. Randomization
will be stratified by gender, disease type and type of
medical center (peripheral or academic) and will be per-
formed by an independent employee at the Department
of Clinical Epidemiology and Biostatistics of the AMC.
Participants assigned to the experimental condition
will start treatment as soon as possible (maximum
within 6 weeks). The second, mid-treatment assessment
will take place four weeks following start of treatment
and the third assessment one month following comple-
tion of treatment. Following the first baseline assess-
ment, participants assigned to the waiting-list control
condition will wait 3,5 months before they are treated
with CBT. This period corresponds to the duration of
the CBT intervention and follow-up assessment of the
experimental group. After this 3,5 month waiting period
the participants in the waiting-list control condition will
be asked to complete a follow-up after waiting/baseline
before CBT assessment before starting treatment. Analo-
gous to the procedure in the experimental condition,
the mid-treatment assessment will take place four weeks
following start of treatment and the follow-up assess-
ment one month following completion of treatment
(see Table 1).
Cognitive behavioral treatment manual
The treatment will consist of eight weekly sessions, each
lasting one hour. The first session will focus on the ra-
tionale of cognitive behavioral therapy, i.e. the influence
of (irrational or dysfunctional) cognitions and attitudes
on (restrictive) feelings and behaviors. Additionally, goal
setting will be initiated. Since patients may have a wide
diversity of psychiatric problems (i.e. PTSD, anxiety
disorders and depression), the treatment manual will
encompass five optional modules for the therapist that
focus on each of these disorders (i.e. exposure based for
anxiety and PTSD, behavioral activation for depression).
The subsequent sessions (2–6) will target teaching the
patient to identify and challenge dysfunctional cogni-
tions and attitudes related to IBD. Each session will
address specific illness-related cognitions. If possible,
dysfunctional cognitions and attitudes will be replaced
Individuals are recruited from four medical centers in the Netherlands. The SF-36 is
administered as part of routine care. If the mental health scale score is ≤ 23, patients are 
eligible for the study and an informed consent is given to the patient.
The researcher is informed by mail which patients fulfill the inclusion criteria (SF-36 mental health scale score ≤ 23, 
a diagnosis of Crohn’s disease or ulcerative colitis, age at or above 18 and sufficient command of Dutch). 
Randomization
Stratified by medical center, disease type and gender.
Exclude
The researcher contacts individuals by phone, asks if they are willing to participate and checks whether informed consent is
received. Participants are globally screened based on main study inclusion (i.e. physically and mentally able to attend eight 
weekly sessions and willing to give written informed consent) and exclusion criteria (current treatment with psychotherapy).
Does participant meet inclusion criteria in telephone 
screening and is patient willing to provide informed consent? 
A date is planned for the administration of the SCID I.
Yes
Experimental condition
Does participant meet further inclusion criteria?
Research team contacts participant and conducts SCID I by phone (T0C: Baseline assessment). Further exclusion 
criteria are substance dependence or abuse and psychosis.
Web based questionnaires (Tbaseline assessment)
Waiting-list control condition
Tbaseline measurement
(Immediately before treatment)
Assessments
Axis-I disorders:
Structured Clinical Interview for DSM-IV (SCID-I
interview)
Quality of Life:
Short Form Health Survey (SF-36), Inflammatory Bowel 
Disease Questionnaire (IBDQ)
Anxiety and Depression:
The Hospital Anxiety and Depression Scale (HADS), The 
Center for Epidemiologic Studies Depression Scale (CES-D)
Dysfunctional Attitudes:
The Dysfunctional Attitude Scale (DAS), 
Disease related cognitions:
The Illness Perception Questionnaire-Revised (IPQ-R),
Coping: The Utrechtse Coping Lijst (UCL) 
No
No Exclude
Yes
Tbaseline measurement
(3,5 months before treatment)
Tmid-treatment measurement
(1 month after start of treatment)
Tfollow -up after waiting/baseline before CBT measurement 
(Immediately before treatment)
Tmid-treatment measurement 
(1 month after start of treatment)
Tfollow -up after CBT measurement
(1 month after end of treatment)
Tfollow -up after CBT measurement
(1 month after end of treatment)
Figure 1 Flow chart study design.
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Table 1 Overview assessment schedule
Measure Description Tbaseline Tfollow-up after waiting/baseline before
CBT
Tmid-
treatment
Tfollow-up after
CBT
Screening SCID-I* DSM-IV-TR
Axis I disorders
Primary Outcome
IBDQ** Inflammatory Bowel Disease Questionnaire E C C E C E C
Secondary
Outcome
SF-36** MOS 36-item Short-Form Health Survey E C C E C E C
HADS** Hospital Anxiety and Depression Scale E C C E C E C
CES-D** The Center for Epidemiologic Studies Depression
Scale
E C C E C E C
P-HBI** Patient-based Harvey Bradshaw Index E C C E C E C
P-SCCAI** Patient-based Simple Clinical Colitis Activity Index E C C E C E C
Potential
Mediators
DAS** Dysfunctional Attitude Scale E C C E C E C
IPQ-R** Illness Perception Questionnaire-Revised E C C E C E C
UCL** Utrechtse Coping Lijst E C C E C E C
Experimental Condition (E) and Waiting list Control Condition (C).
* Interview that is administered by telephone.
**Web-based questionnaire.
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dysfunctional cognitions are realistic and reflect the lim-
itations that the disease imposes. Such thoughts will be
worked through and intervention will focus on accept-
ance of these disease limitations. Finally, in the last two
sessions, the newly learned cognitions and attitudes will
be consolidated using specific CBT techniques such as
flashcards with helpful cognitions or attitudes. As cus-
tomary within CBT, each session patients will be given
homework. The CBT will be conducted by registered
psychotherapists, specialized in cognitive behavioral
therapy.
All treatment sessions will be audio-recorded and
therapists will receive feedback over the first two CBT
treatments to promote treatment integrity. Additionally,
regular supervision will be provided.
Module 1: identify and tackle avoidance behavior
During this module the patient will learn to identify his/
her avoidance behavior in daily life that has an impact
on anxiety and depressive symptoms. These symptoms
lead to either an increase of anxiety and thereby an
increase of avoidance behavior or to less interest while
undertaking the activities and less satisfaction. This
vicious circle and the importance of breaking this pat-
tern will be explained to the patient. This will be done
by identifying what specific situations are avoided by
the patient in daily life and by eventually replacing
avoidance behavior by alternative behavior. In case ofdepression the therapist will stimulate behavioral change
by helping patients to become more active by increasing
mood independent potential pleasurable (reinforcing)
activities in their lives (behavior activation) [19-21]. The
ultimate goal is to teach patients to actively react to
difficult or painful situations or emotions instead of
avoiding them (becoming pro-active rather than reactive
to mood swings) [19].
Module 2: illness-history writing assignment
IBD patients often have a long illness history. This may
consist of unprocessed negative experiences. For emo-
tional processing of these negative experiences it is im-
portant that these experiences are identified and
processed. Therefore, the patient will be asked to write
about the most painful memories of his/her illness his-
tory in order to stimulate the processing of that memory
[22,23]. The most painful memories are usually the ones
that are being avoided or suppressed. The patient will
write as detailed as possible about the most painful
images (e.g. physician’s face, surgeon, hospital appli-
ances, intensive care unit), thoughts (e.g. it is my fault,
I am going to die) and emotions (e.g. embarrassment,
feeling dirty and helpless). In a subsequent session the
patient will read the most painful pieces of the assign-
ment out loud. In this way the patient will be exposed to
the most painful images, cognitions and emotions. Add-
itionally, the therapist will identify the dysfunctional
cognitions and attitudes of the patient.
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The patient may experience intruding traumatic illness-
related memories (flashbacks). During imagery with
rescripting the patient will re-experience and rewrite the
most painful memories in his/her imagination. Together
the patient and therapist will compose a hierarchy of
fearful situations and choose one or more of the most
traumatic experiences to work through during imagery
with rescripting. The patient will be asked to imagine
the traumatic situation as lively as possible. After suffi-
cient exposure the experience must be “re-written”
following three phases. This will be done by returning to
the negative experience in the patient’s imagination and
altering it into satisfying new feelings, helpful attitudes
and corrective experiences (e.g. support or presence of
partner/parent) [24-26].
Module 4: cognitive therapy
In order to decrease emotions such as fear, sadness and
anger cognitive therapy focuses on automatic negative
thoughts and underlying dysfunctional attitudes that
lead to these emotions. The cognitive model states that
attitudes develop during childhood and are based on
particular life events and/or views of significant others
(e.g. parents or teachers) [12,27]. This determines one’s
interpretation of one self, others and the world. For
instance, an early experience such as being bullied at
school can trigger the activation of dysfunctional atti-
tudes such as ‘I am worthless’. Later in life, when a crit-
ical event, such as the diagnosis of IBD takes place, the
dysfunctional attitudes may be activated. These, in turn,
activate negative or anxious automatic thoughts such as
‘Now that I am sick, I am worthless’. These negative
automatic thoughts can in turn cause anxiety and
depressive symptoms. The ultimate aim of this module
is to identify, challenge and alter dysfunctional attitudes
of patients into helpful ones that fit in the current
circumstances [28].
Module 5: relapse prevention plan
During the last two sessions the therapist will work with
the patient on the steps that can be undertaken in order
to prevent relapse. The patient will learn to signal poten-
tial relapse (e.g. symptoms like worrying, avoiding activ-
ities) and to develop prevention strategies. For instance,
the patient might make use of tools such as flash cards
with helpful attitudes, in order not to spiral back into
the old dysfunctional ones [28].
Sample size
We will consider a difference of 0.5 standard deviation,
which is equal to a moderate effect size [29], clinically
relevant. For calculating the required difference on the
Inflammatory Bowel Disease Questionnaire (IBDQ), wewill use the data from a study by McColl et al [30]
among 111 IBD patients. The mean IBDQ score was 182
and the standard deviation was 59. A 0.5 standard devi-
ation thus equals approximately 30 points on a scale
ranging from 32 to 224. With an effect size of 0.5 stand-
ard deviation, an alpha level of 0.05, and a power of
80%, at least 34 patients in both the experimental condi-
tion and the waiting list control condition are needed.
Given a potential attrition rate of 10%, we will include
40 patients in each condition.
Feasibility
Approximately 1600 IBD patients are treated at the
AMC on a yearly basis. Given the fact that patients may
be eligible regardless of time since diagnosis, the number
of patients to be included in only one center is feasible.
However, to enhance recruitment in a relatively short
time period and promote future dissemination we
will recruit patients in three additional medical centers
(i.e. Slotervaart-hospital, Flevo-hospital and VUmc).
Two of the four participating centers are academical
medical centers (i.e. AMC and VUmc). Based on the
literature [31], we expect 10-20% of the IBD patients to
have a score below the cut-off point and be eligible for
the study.
Inclusion criteria and exclusion criteria
Inclusion criteria will be: (1) a diagnosis of Crohn’s
disease or ulcerative colitis; (2) age above 18; (3) a score
of 23 or lower on the mental health scale of the SF-36;
(4) physically and mentally able to attend eight weekly
sessions; and (5) sufficient command of Dutch. Exclu-
sion criteria will be: (1) current psychological treatment;
and (2) known psychiatric disorders that may complicate
treatment (current substance dependence or abuse,
current psychosis).
Recruitment and informed consent
Patients who have a score of 23 or lower on the mental
health subscale will be eligible for the study. The mental
health subscale consists of 5 items that require a re-
sponse on a 6-point scale (range 5–30). The cut-off
score of 23 is chosen as scores of 23 or lower are found
indicative (with a high level of sensitivity and specificity)
of depression and anxiety in primary care patients [17].
If this step is ignored a failure of a positive effect may be
contributed to high baseline scores and lack of room for
further improvement [15]. Consequently, the researcher
will contact patients by telephone to ask whether they
are willing to participate and to check whether informed
consent is received. If the participant meets all inclusion
criteria and is willing to provide informed consent, an
appointment will be made to administer the SCID-I by
telephone.
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before randomisation.
Outcome measures
Sociodemographic assessment will include age, gender,
educational level, employment status, marital status,
ethnicity, and treatment center.
Clinical physical data will be completed by the treat-
ing gastroenterologist, and will include type of disease
(Crohn’s disease and ulcerative colitis), date of onset
of disease, having a colostomy, and number of opera-
tions. Finally, the biological markers of disease activity
(e.g. C-reactive protein (CRP)) of each patient attending
the outpatient department will be registered in an elec-
tronic database. Additionally disease activity will be mea-
sured using the following illness specific questionnaires:
the Harvey Bradshaw index (P-HBI) for patients with
Crohn’s disease and Simple Clinical Colitis Activity
Index (P-SCCAI) for patients with ulcerative colitis.
These patient-based questionnaires were specially devel-
oped for the current study [32]. The original SCCAI has
good validity and reliability [33].
Primary outcome measures the Inflammatory Bowel
Disease Questionnaire (IBDQ) will be used to assess the
primary outcome of the intervention [34]. The IBDQ
measures health-related quality of life and consists of 32
items assessing four dimensions: bowel symptoms, sys-
temic symptoms, emotional functioning, and social func-
tioning. In addition to these four subscale scores, a total
score can be calculated [20]. The IBDQ has good con-
struct and criterion validity, test-retest reliability and
high internal consistency [35].
Secondary outcome measures the MOS SF-36 is a
36-item questionnaire assessing generic health-related
quality of life or health status [36]. The items can be
aggregated into a Physical Component Summary score
and a Mental Component Summary score. The SF-36
has high internal consistency and good reliability and
discriminant validity [37].
The Hospital Anxiety and Depression Scale (HADS)
assesses the possible presence of anxiety and depressive
states [38,39]. The HADS is considered to be unbiased
by the presence of somatic illness and is found to be
reliable and valid [40]. It consists of two sub-scales,
anxiety and depression, both containing seven items.
The CES-D scale (The Center for Epidemiologic Studies
Depression Scale) is a short self-report scale designed to
measure depressive symptomatology in the general
population. The CES-D has high internal consistency,
satisfactory test-retest reliability and excellent concur-
rent validity [41].
Mediation variables The Illness Perception Questionnaire-
Revised (IPQ-R) assesses illness-related cognitions. The 48
items measure seven dimensions: timeline acute/chronic,timeline cyclical, consequences, personal control, treat-
ment control, illness coherence and emotional representa-
tions. The IPQ-R has good internal and test-retest
reliability and predictive and discriminant validity [42].
The 40-item Dysfunctional Attitude Scale (DAS) mea-
sures dysfunctional attitudes, including excessive and
rigid beliefs [43]. The DAS has good psychometric prop-
erties regarding reliability, internal consistency and
convergent construct validity [44].
The Utrechtse Coping Lijst (UCL) assesses general
coping behavior in problem situations [45,46]. The
subscales ‘problem-solving’ (7 items) and ‘avoidance’
(8 items) will be used. The UCL has good test-retest
reliability, construct and predictive validity [47].
All standard self-report questionnaires fulfill the follow-
ing selection criteria. They: (a) are relatively brief, (b) have
sufficient breadth of coverage, (c) are widely used, and (d)
yield adequate to high levels of reliability and validity.
An overview of the questionnaires at the different time
points for the experimental and waiting-list control
conditions is provided (see Table 1).
Withdrawal
Subjects can withdraw from the study at any time for any
reason if they wish to do so without any consequences.
Nevertheless, we will ask those who withdraw from CBT
treatment if they are willing to complete the web-based
questionnaires at the respective time intervals.
Safety monitoring and reporting
The study will be conducted according to the principles
of the Declaration of Helsinki and in accordance with
the Medical Research Involving Human Subjects Act
(WMO).
The Medical Ethical Committee (MEC) of the AMC
offers exemption from participants insurance.
In general there will be few if any risks associated with
the research in question. Since there is no indication
and no evidence that the intervention might be harmful
to patients, we will not anticipate premature termination
of the study. Clearly, each individual patient has the
right to withdraw from the study at any time he/she
wishes.
Suspected serious adverse events will be recorded and
reported to the MEC of the AMC.
Statistical analysis
Analyses of covariance will be conducted to determine
the extent to which treated patients (experimental con-
dition) show more improvement on the primary and
secondary outcome variables compared to patients in
the waiting-list control condition. A two-way factorial
analysis of variance with the between-factor condition
(experimental condition versus waiting list control
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used. Moreover, stratification variables, i.e. gender, treat-
ment center and disease type will be included as covari-
ates in the analyses (ANCOVA).
Additionally, the data of experimental and the waiting-
list control condition will be pooled, to measure the
overall effect of treatment. Before the two groups will be
pooled, we will examine whether there is a difference in
effect for the experimental versus the waiting-list control
condition (Delta Tfollow-up after CBT-Tbaseline before CBT). In
case differences emerge, this will be stratified reported.
For therapy effects, data will be analysed on an
intention to treat (ITT) as well as treatment completer
basis. The completers sample will include patients who
attend at least 5 CBT sessions.
To express the magnitude of the effects, mean gain
scores on the outcome measures will be standardized to
Cohen’s d, representing the number of standard devia-
tions separating the two means. Point estimates and 95%
confidence intervals of d will be determined for the
within and the between group effects. Between effect
sizes will be calculated using the pooled standard devi-
ation (of the baseline scores) and confidence intervals
will be approximated from the central t-distribution.
Effect of CBT on quality of life mediated by cognitions,
attitudes and coping
We will subsequently examine the extent to which
changes in quality of life will be mediated by improve-
ments in illness-cognitions, attitudes and coping styles
and whether this change is associated with outcome.
Discussion
Given its chronic nature and frequently reported poor
quality of life for many patients, IBD is often associated
with anxiety and depression. Apart from medical treat-
ment, psychological intervention might be a crucial
component of treatment of IBD patients and is needed
alongside medical treatment [8,9]. Results from a recent
meta-analysis of psychological interventions for treat-
ment of IBD showed that current psychological treat-
ment is not effective among IBD patients [15]. These
disappointing results can, however, be attributed to spe-
cific treatment programs and a number of methodological
short-comings of the evaluation studies. Therefore a fur-
ther and more stringent study of psychological interven-
tions in IBD patients to enhance quality of life and reduce
anxiety and depression is warranted.
A number of strengths of the current study merit
attention. First, it will offer a cognitive behavioral treat-
ment manual, which is specifically tailored to the needs
of IBD patients. Due to the focus on specific worries and
needs of IBD patients, this treatment may be effective in
enhancing quality of life and alleviating psychologicalsymptoms, such as anxiety and depression associated
with IBD. Additionally, this trial will allow us to investi-
gate and learn more about the mechanisms of CBT. Par-
ticularly, illness-related cognitions, dysfunctional attitudes
and coping behaviors (i.e. problem solving and avoidance)
will be examined in order to understand the most effective
components of CBT.
Second, only patients with a poor level of mental quality
of life will be included. These patients are the ones who are
most in need of psychological help. To the best of our
knowledge, no study has previously selected patients based
on their initial well-being. However, Larsson et. al. included
their patients on another aspect of mental well-being, i.e.
anxiety and depressive symptoms (patients with a high
HADS anxiety levels) [16]. In this study an education pro-
gram was employed instead of CBT, potentially explaining
the lack of effect in the preselected patient group.
A third strength of the current study will be the
random assignment of patients to the experimental
group and the waiting list control group. To ensure an
equal distribution among these two groups patients will
be stratified by gender, treatment center and disease
type. These factors are selected for several reasons. First,
previous research found that disease course may differ
for female and male patients. Particularly, females pos-
sibly have a higher risk of disease activity relapse than
males [48]. Females, therefore, may have more psycho-
logical symptoms. Second, patients will be stratified by
treatment center. A distinction will be made between an
academic setting and a peripheral setting. We expect
that an academic hospital would treat more severe cases
of IBD than a peripheral setting. Finally, disease type is
also used as a stratification factor. Previous research has
found that CD patients undergo more surgical interven-
tions and experience more disease exacerbations than
UC patients [49]. This indicates that CD is a more com-
plex disorder than UC. Additionally, CD patients report
a poorer quality of life and more anxiety symptoms than
UC patients [49,50]. Therefore, it is important that UC
and CD patients are distributed evenly in the experimen-
tal group and the waiting list control group.
In sum, there is a compelling need to enhance the
quality of life of patients with IBD, especially in patients
with a low level quality of life. CBT may be the most
promising intervention given its empirical status over 5
decades [12,27]. It is expected to enhance the quality of life
of IBD patients. Poor quality of life is not only a conse-
quence of the disease but may in itself be a causal factor.
It may induce a higher level of symptom severity, more
reporting of unexplained physical symptoms and poorer
treatment adherence. If found feasible and effective, this
illness-oriented CBT is a first step to enhance poor quality
of life in patients with IBD and, possibly, other gastro-
enterological diseases.
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